As IDO1 activity correlates with systemic inflammation, we surmise that more pronounced baseline inflammation in the previous cohort of patients with advanced atherosclerosis, all of whom underwent either revascularization or amputation, compared to the claudicants in the current cohort, accounts for the differences in metabolomics profiles. The gene discussed is IDO1; the disease is atherosclerosis.